title: Hip migration percentage in children with cerebral palsy treated with botulinum toxin type A.
abstract: OBJECTIVE
  To determine hip radiographic findings in children with cerebral palsy (CP) treated with botulinum toxin type A (BTX-A).
  
  
  METHODS
  Retrospective chart review with correlation to radiographic findings.
  
  
  METHODS
  Academic center.
  
  
  METHODS
  Sixteen subjects with CP.
  
  
  METHODS
  BTX-A treatment to adductor muscles.
  
  
  METHODS
  The Reimers hip migration percentage before and after BTX-A.
  
  
  RESULTS
  Thirty-two hips in 16 children with CP were treated. We examined the effect of initial migration percentage and initial migration percentage age on the change in migration percentage after BTX-A injection. A significant effect for initial migration percentage (<30% or >/=30%; F=19.05, P <.001) and a significant interaction between initial migration percentage and initial migration percentage age (F=7.5, P <.01) was noted. Initial migration percentage age (</=24 mo or >24 mo) was not significant (F=.95, P =.34). Patients who had an initial migration percentage of 30% or more and were less than 24 months old were more likely to have a decrease in migration percentage after BTX-A injection compared with patients who were older than 24 months and who had an initial migration percentage of 30% or more.
  
  
  CONCLUSIONS
  Improvement in hip migration percentage after BTX-A injection is a function of age and the initial migration percentage. BTX-A injections to adductor muscles may be beneficial for some children with CP.
authors.affiliation: Department of Physical Medicine and Rehabilitation, Baltimore, MD, USA. pidcock@kennedykrieger.org
authors.forename: Frank S
authors.initials: FS
authors.lastname: Pidcock
authors.forename: David E
authors.initials: DE
authors.lastname: Fish
authors.forename: Doug
authors.initials: D
authors.lastname: Johnson-Greene
authors.forename: Isabel
authors.initials: I
authors.lastname: Borras
authors.forename: John
authors.initials: J
authors.lastname: McGready
authors.forename: Charles E
authors.initials: CE
authors.lastname: Silberstein
mesh_terms: D000375:Aging; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000188:drug therapy* / Q000534:rehabilitation; D002675:Child, Preschool; D005260:Female; D006615:Hip / Q000000981:diagnostic imaging*; D006801:Humans; D007223:Infant; D008297:Male; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D011859:Radiography; D012189:Retrospective Studies
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A